John Orloff Biography and Net Worth

John Orloff, MD, is Executive Vice President, Head of Research & Development of Alexion. Dr. Orloff is focused on strengthening Alexion’s clinical pipeline and research programs, enhancing research and development productivity, overseeing regulatory and medical affairs, and supporting business development. Dr. Orloff has 20 years of experience in the biopharmaceutical industry and deep expertise spanning various stages of clinical and non-clinical development, including developing medicines for rare diseases.

Prior to joining Alexion, Dr. Orloff served as Executive Vice President, Head of Research & Development at Novelion, where he currently sits on the Board of Directors. He previously served with Baxalta as Global Head of R&D and Chief Scientific Officer, where he advanced the company’s pipeline and oversaw regulatory approval of 10 unique products and two devices. He also held executive R&D roles with Baxter International, Merck Serono, Novartis and Merck Research Laboratories. Prior to joining the biopharmaceutical industry in 1997, Dr. Orloff was with the Yale School of Medicine for seven years.

Dr. Orloff graduated magna cum laude from Dartmouth College, received his medical degree from the University of Vermont, and completed internal medicine training at the University of Pittsburgh, serving as Chief Medical Resident.

What is John J. Orloff's net worth?: The estimated net worth of John J. Orloff is at least $5.80 million as of June 8th, 2018. Dr. Orloff owns 31,790 shares of Alexion Pharmaceuticals stock worth more than $5,801,675 as of December 23rd. This net worth evaluation does not reflect any other assets that Dr. Orloff may own. Additionally, Dr. Orloff receives an annual salary of $1,830,000.00 as EVP at Alexion Pharmaceuticals. Learn More about John J. Orloff's net worth.
How old is John J. Orloff?: Dr. Orloff is currently 64 years old. There are 5 older executives and no younger executives at Alexion Pharmaceuticals. Learn More on John J. Orloff's age.
What is John J. Orloff's salary?: As the EVP of Alexion Pharmaceuticals, Inc., Dr. Orloff earns $1,830,000.00 per year. The highest earning executive at Alexion Pharmaceuticals is Dr. Ludwig N. Hantson, CEO & Director, who commands a salary of $4,250,000.00 per year. Learn More on John J. Orloff's salary.
How do I contact John J. Orloff?: The corporate mailing address for Dr. Orloff and other Alexion Pharmaceuticals executives is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. Alexion Pharmaceuticals can also be reached via phone at 475-230-2596 and via email at [email protected]. Learn More on John J. Orloff's contact information.
Has John J. Orloff been buying or selling shares of Alexion Pharmaceuticals?: John J. Orloff has not been actively trading shares of Alexion Pharmaceuticals within the last three months. Most recently, John J. Orloff sold 2,115 shares of the business's stock in a transaction on Friday, June 8th. The shares were sold at an average price of $118.53, for a transaction totalling $250,690.95. Following the completion of the sale, the executive vice president now directly owns 31,790 shares of the company's stock, valued at $3,768,068.70. Learn More on John J. Orloff's trading history.
Who are Alexion Pharmaceuticals' active insiders?: Alexion Pharmaceuticals' insider roster includes Daniel Bazarko (CAO), Tanisha Carino (CAO), Paul Clancy (CFO), Indrani Franchini (EVP), Ludwig Hantson (CEO & Director), John Orloff (EVP), Vikas Sinha (CFO), and Heidi Wagner (SVP). Learn More on Alexion Pharmaceuticals' active insiders.

John J. Orloff Insider Trading History at Alexion Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/8/2018	Sell	2,115	$118.53	$250,690.95	31,790

John J. Orloff Buying and Selling Activity at Alexion Pharmaceuticals

Alexion Pharmaceuticals Company Overview

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $182.50

$182.50

50 Day Range

MA: $182.82

$179.45

$186.61

2 Week Range

Now: $182.50

$99.91

$187.45

Volume

10 shs

Average Volume

3,309,941 shs

Market Capitalization

$40.34 billion

P/E Ratio

59.64

Dividend Yield

N/A

Beta

1.25

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

John Orloff Biography and Net Worth

What is John J. Orloff's net worth?

How old is John J. Orloff?

What is John J. Orloff's salary?

How do I contact John J. Orloff?

Has John J. Orloff been buying or selling shares of Alexion Pharmaceuticals?

Who are Alexion Pharmaceuticals' active insiders?